Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Pack Size | SKU | Availability | Price |
|---|
About This Item
Empirical Formula (Hill Notation):
C19H18ClN3O5S
CAS Number:
Molecular Weight:
435.88
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Pricing and availability is not currently available.
Product Name
Rivaroxaban, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -34 to -44, c = 0.3 in DMSO
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[s]1c(ccc1C(=O)NC[C@@H]2OC(=O)N(C2)c3ccc(cc3)N4CCOCC4=O)Cl
InChI
1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
InChI key
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
Biochem/physiol Actions
Rivaroxaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (IC50 = 0.7 nM; no activity against thrombin, trypsin, plasmin, FVIIa, FIXa, FXIa, urokinase, or activated protein C up to 20 μM) with good anticoagulant activity in vitro (dose for doubling fibrin formation time = 230/300 nM in human/rat plasma) and antithrombotic efficacy in vivo (ED50 = 1 mg/kg i.v. or 5 mg/kg p.o. by rat arteriovenous shunt model).
1 of 1
This Item | |||
|---|---|---|---|
| assay ≥98% (HPLC) | assay - | assay - | assay - |
| form powder | form - | form - | form - |
| Quality Level 100 | Quality Level - | Quality Level - | Quality Level - |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: 2 mg/mL, clear | solubility - | solubility - | solubility - |
| color white to beige | color - | color - | color - |
Still not finding the right product?
Explore all of our products under Rivaroxaban
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 2
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Bart J Biemond et al.
Thrombosis and haemostasis, 97(3), 471-477 (2007-03-06)
Current anticoagulant therapies for the prevention and treatment of thromboembolic disorders have many drawbacks: vitamin K antagonists interact with food and drugs and require frequent laboratory monitoring, and heparins require parenteral administration. Oral rivaroxaban (BAY 597939) is a new, highly
E Jacqueroux et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 148, 27-37 (2020-01-17)
ABC transporters, such as P-gp and BCRP, are involved in rivaroxaban pharmacokinetics and can lead to drug-drug interactions (DDIs). Investigations of the victim role for rivaroxaban and transporter-mediated DDI are commonly performed using in vitro models. However, interpretation of rivaroxaban
In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
G T Gerotziafas et al.
Journal of thrombosis and haemostasis : JTH, 5(4), 886-888 (2007-03-29)
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2844-5MG | 04061842334568 |
| SML2844-25MG | 04061842334551 |


